This work contains updated and clinically relevant information about tuberculosis. It is aimed at providing a succinct overview of history and disease epidemiology, clinical presentation and the most recent scientific developments in the field of tuberculosis research, with an emphasis on diagnosis and treatment. It may serve as a practical resource for students, clinicians and researchers who work in the field of infectious diseases.

Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimicrobial resistance pose particular challenges in combating these diseases. Major Infectious Diseases identifies feasible, cost-effective packages of interventions and strategies across delivery platforms to prevent and treat HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and neglected tropical diseases. The volume emphasizes the need to effectively address emerging antimicrobial resistance, strengthen health systems, and increase access to care. The attainable goals are to reduce incidence, develop innovative approaches, and optimize existing tools in resource-constrained settings.

An annual death toll of 2 million, coupled with rising drug resistance, highlights the need for the development of new drugs, better diagnostics, and a tuberculosis (TB) vaccine. Addressing these key issues, A Color Atlas of Comparative Pathology of Pulmonary Tuberculosis introduces TB histopathology to the non-histopathologists, students, scientis

Before effective treatments were introduced in the 1950s, tuberculosis was a leading cause of death and disability in the United States. Health care workers were at particular risk. Although the occupational risk of tuberculosis has been declining in recent years, this new book from the Institute of Medicine concludes that vigilance in tuberculosis control is still needed in workplaces and communities. Tuberculosis in the Workplace reviews evidence about the effectiveness of control measuresâ€"such as those recommended by the Centers for Disease Control and Preventionâ€"intended to prevent transmission of tuberculosis in health care and other workplaces. It discusses whether proposed regulations from the Occupational Safety and Health Administration would likely increase or sustain compliance with effective control measures and would allow adequate flexibility to adapt measures to the degree of risk facing workers.

It is estimated that one third of the world's population is infected with Mycobacterium tuberculosis (the bacterium that causes tuberculosis (TB)), and that each year, about 9 million people develop TB, of whom about 2 million die. Of the 9 million annual TB cases, about 1 million (11%) occur in children (under 15 years of age). Of these childhood cases, 75% occur annually in 22 high-burden countries that together account for 80% of the world's estimated incident cases. In countries worldwide, the reported percentage of all TB cases occurring in children varies from 3% to more than 25%. The Stop TB Strategy, which builds on the DOTS strategy developed by the World Health Organization (WHO) and the International Union Against TB and Lung Disease, has a critical role in reducing the worldwide burden of disease and thus in protecting children from infection and disease. The management of children with TB should be in line with the Stop TB Strategy, taking into consideration the particular epidemiology and clinical presentation of TB in children. These consensus guidelines were produced to help the National Tuberculosis Programmes on the management of tuberculosis in children.

Chapter 1. Introduction -- chapter 2. Disease burden and 2015 targets assessment -- chapter 3. TB case notifications and treatment outcomes -- chapter 4. Drug-resistant TB -- chapter 5. Diagnostics and laboratory strengthening -- chapter 6. Addressing the co-epidemics of TB and HIV -- chapter 7. Financing -- chapter 8. Research and development -- Annexes.

Completely updated and revised, Clinical Tuberculosis continues to provide the TB practitioner-whether in public health, laboratory science or clinical practice-with a synoptic and definitive account of the latest methods of diagnosis, treatment and control of this challenging and debilitating disease.New in the Fifth Edition:Gamma interferon-based

The Microbiology of Respiratory System Infections reviews modern approaches in the diagnosis, treatment, and prophylaxis of respiratory system infections. The book is very useful for researchers, scientists, academics, medical practitioners, graduate and postgraduate students, and specialists from pharmaceutical and laboratory diagnostic companies. The book has been divided into three sections according to the types of respiratory pathogens. The first section contains reviews on the most common and epidemiologically important respiratory viruses, such as influenza virus, severe acute respiratory system coronavirus, and recently discovered Middle East respiratory syndrome coronavirus. The second section is devoted to bacterial and fungal pathogens, which discusses etiology and pathogenesis including infections in patients with compromised immune system, and infections caused by fungal pathogens, such as Aspergillus and Pneumocystis. The third section incorporates treatment approaches against different types of bacterial infections of the lower respiratory tract. This section reviews classical antimicrobial and phytomedical approaches as well as the application of nanotechnology against respiratory pathogens. - Offers the most up to date information on the microbiology of lower respiratory system infections - Features contributors from across the world, presenting questions of interest to readers of both developed and developing countries - Reviews the most common and epidemiologically important respiratory viruses - Discusses the etiology and pathogenesis of bacterial and fungal pathogens including infections in patients with compromised immune system, and infections caused by fungal pathogens, such as Aspergillus and Pneumocystis